- Home
- BLTE
BLTE
Belite Bio Inc
as of 04-16-2026 1:25pm EST
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.5B | IPO Year: | 2021 |
| Target Price: | $198.00 | AVG Volume (30 days): | 138.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $53.59 - $200.00 | Next Earning Date: | 05-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 492.11% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered BLTE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Belite Bio Inc (BLTE)
Chief Executive Officer
Avg Cost/Share
$181.77
Shares
9,200
Total Value
$1,669,338.90
Owned After
177,634
Director
Avg Cost/Share
$180.43
Shares
1,100
Total Value
$198,473.11
Owned After
9,096
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$181.85
Shares
6,200
Total Value
$1,125,303.44
Owned After
98,000
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lin Yu-Hsin | BLTE | Chief Executive Officer | Apr 9, 2026 | Sell | $181.77 | 9,200 | $1,669,338.90 | 177,634 | |
| Chen Wan-Shan | BLTE | Director | Apr 9, 2026 | Sell | $180.43 | 1,100 | $198,473.11 | 9,096 | |
| Chuang Hao-Yuan | BLTE | Chief Financial Officer | Apr 9, 2026 | Sell | $181.85 | 6,200 | $1,125,303.44 | 98,000 |
Compare BLTE vs Leading Stocks
See how BLTE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BLTE Belite Bio Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.